Antidepressants as Endocrine Disrupting Compounds in Fish

William Andrew Thompson and Mathilakath M. Vijayan*
Department of Biological Sciences, University of Calgary, Calgary, AB, Canada

As antidepressant usage by the global population continues to increase, their persistent detection in aquatic habitats from municipal wastewater effluent release has led to concerns of possible impacts on non-target organisms, including fish. These pharmaceuticals have been marketed as mood-altering drugs, specifically targeting the monoaminergic signaling in the brain of humans. However, the monoaminergic systems are highly conserved and involved in the modulation of a multitude of endocrine functions in vertebrates. While most studies exploring possible impact of antidepressants on fish have focused on behavioural perturbations, a smaller spotlight has been placed on the endocrine functions, especially related to reproduction, growth, and the stress response. The purpose of this review is to highlight the possible role of antidepressants as endocrine disruptors in fish. While studies linking the effects of environmentally relevant levels of antidepressant on the endocrine system in fish are sparse, the emerging evidence suggests that early-life exposure to these compounds have the potential to alter the developmental programming of the endocrine system, which could persist as long-term and multigenerational effects in teleosts.

Keywords: hormones, reproduction, growth, stress response, monoamines, steroids, pharmaceutical, municipal wastewater effluent

INTRODUCTION

Antidepressants in aquatic environments have persisted for decades and are continually introduced into our waterways through municipal wastewater effluent (MWWE) release (1). Aquatic organisms, including fish, inhabiting these waterways are persistently exposed to these compounds, but effects on non-target organisms are only beginning to emerge (2, 3). Over the last few decades, studies have examined the effects of antidepressants on teleosts, but the majority of work have focused on behavioural alterations (4–6). Monoamines, including serotonin, noradrenaline, and dopamine, are the main targets by which the antidepressants elicit a behavioural response (7). However, monoamines play significant roles in modulating other endocrine functions, including steroid hormone synthesis and action (8–13), suggesting wider impact on the physiology of fishes due to antidepressant exposures. As recent reviews have discussed the impact of antidepressants on behavioral consequences (5, 6), this minireview will be limited to the endocrine-related perturbations in fish. Here, we highlight the emerging evidence of antidepressants as endocrine disrupting compounds in fish.
ANTIDEPRESSANTS IN THE AQUATIC ENVIRONMENT

Since the use of anti-histaminergic compounds in the early 1950’s, the practice of neuroactive compounds to treat behavioural deficits associated with major depressive disorder has grown (14–16). The advent of selective serotonin reuptake inhibitors (SSRI) reshaped the antidepressant market, and prescriptions increased rapidly in the early 1990s, especially with the release of fluoxetine (Prozac), citalopram (Celexa), fluvoxamine (Luvox), paroxetine (Paxil), and sertraline (Zoloft; 17). To diminish the side-effects associated with the SSRI class of compounds, additional antidepressants targeting the inhibition of reuptake of either noradrenaline (NRI), such as reboxetine (Edronax), or both serotonin and noradrenaline (SNRI), such as venlafaxine (Effexor) and duloxetine (Cymbalta), emerged (17).

In humans, antidepressants typically undergo first-pass metabolism in the liver (18), and in many cases their metabolites, including norfluoxetine (fluoxetine), O-desmethylvenlafaxine (venlafaxine), and desmethylcitalopram (citalopram), remain equipotent to the parent compound (19). Consequently, excretion of these drugs, and the incomplete removal by wastewater treatment processes, has led to the antidepressants, including citalopram, sertraline, venlafaxine, fluoxetine, and other neuroactive compounds, being prevalent in MWWE at concentrations greater than parts per billion (20–27). Also, given their continued release into the environment and their slower breakdown, antidepressants are being touted as persistent contaminants in the aquatic environment (28).

Given that antidepressants consumption has grown up in the last 20 years and is only expected to increase (29, 30), environmental levels will also increase in our waterways receiving MWWE outfalls. Consequently, understanding the impact of these drugs on non-target animals, such as fishes, and deciphering their mode of action leading to the adverse effects, will allow for developing environmental risk assessment models for antidepressants in our waterways.

ANTIDEPRESSANT EFFECTS ON MONOAmine CONTENT IN FISH

In humans, antidepressants primarily target the transporters of monoamines, including serotonin, noradrenaline, and dopamine, inhibiting the reuptake of monoamines from the synaptic cleft into the presynaptic cell (6, 31). This increases the duration of exposure, as well as the concentration of monoamines in the synapse, leading to increased interaction with receptors on the postsynaptic terminal for therapeutic benefits (31, 32). In teleosts, studies have demonstrated that antidepressants interact with the monoamine transporters, and disrupt brain monoamines content (33–41). For instance, both fluoxetine and venlafaxine reduced brain serotonin levels in adult hybrid striped bass (Morone saxatilis; 33, 37, 38) and Siamese fighting fish (Betta splendens; 35). Also, exposures to venlafaxine elevated serotonin, noradrenaline, and dopamine contents in a region-specific manner in the midbrain of juvenile rainbow trout (Oncorhynchus mykiss; 36). Early developmental exposure to venlafaxine depleted serotonin immunoreactivity in the larval zebrafish (Danio rerio) brain and reduced catecholamine cell populations (39). These results suggest that antidepressants impact on brain monoamine content in fishes may be species- and/or life-stage-specific (6, 13), but a clear cause and effect relationship has not been established.

ANTIDEPRESSANTS EFFECT ON THE ENDOCRINE SYSTEMS IN FISH

The monoaminergic system is highly conserved in vertebrates, and the central and peripheral monoamines play an important role in modulating endocrine functions (3, 8–10, 12, 42–49). Consequently, disruptions in the monoaminergic pathway is a potential target for antidepressants effect on the endocrine system (6, 13). Very little is known about the mode of action of antidepressants in disrupting the endocrine axes in teleosts. Here we will outline some of the studies that suggest that the antidepressants are endocrine disruptors, especially pertaining to reproduction, growth, and the stress response in fish.

Reproduction

Reproduction is primarily under the control of the hypothalamic-pituitary-gonadal (HPG) axis in fish (9, 50). The hypothalamus releases gonadotropin releasing hormone (GnRH), the primary endocrine signal for the release of the pituitary gonadotropins, including the follicular stimulating hormone (FSH) and luteinizing hormone (LH), into the circulation (50, 51). The actions of LH and FSH stimulates the secretion of the sex steroids, including androgens and estrogens/progestins, essential for spermatogenesis and oogenesis, respectively (52). There is evidence that antidepressants, both SSRI’s and the SNRI’s, affect reproductive performance in fish (see Table I for specific experimental information). For instance, fluoxetine exposure for 100 d delayed the onset of sexual maturation in the male mosquitofish (Gambusia affinis; 53). Also, fluoxetine exposure for over 7 d increased estrogen level, while reducing testosterone level and the milt volume in the male goldfish (Carassius auratus; 55). Citalopram exposure reduced whole-brain GnRH transcripts and disrupted spermatogenesis in male zebrafish (78). In females, fluoxetine exposure reduced estradiol levels in the ovary, and this correlated with a drop in egg production in zebrafish (56). A similar result was also seen in goldfish, with fluoxetine injection leading to significant reductions in circulating estradiol levels (54). Venlafaxine exposure also reduced egg production in adult zebrafish (78). Although these studies suggest that both the SSRI and the SNRI class of antidepressants have the potential to affect fish reproduction, the concentrations utilized in these studies were high and not environmentally realistic. Few studies have assessed reproductive parameters in fish upon exposure to environmentally relevant concentrations. For instance, fluoxetine (0.1 ug/L) exposure for 4 weeks perturbed estradiol
| Drug | Species (sex) | Treatment | Effects | Reference |
|------|---------------|------------|---------|-----------|
| **Reproduction** | | | | |
| **Fluoxetine** | Mosquitofish (Gambusia affinis; both sexes) | 59 to 159 days post fertilization (juvenile to adult) to 71 µg/L [W.E] | Delayed maturation of sexual morphology | (53) |
| | Goldfish (Carassius auratus; females) | 14-day adult exposure to 5 µg/g body weight [I.P] | Reduced circulating estradiol, and transcript levels of ERβ1 in the telencephalon and hypothalamus, and ERα in the telencephalon | (54) |
| | Goldfish (males) | 7- or 14- day adult exposure to 0.54 or 54 µg/L [W.E] | Reduced milt volume, increased plasma estradiol, and increased transcript abundance of testicular fshr, and cyp19a at 54 µg/L | (55) |
| | Zebradorn (Dario rerio; females) | Adult exposure to 32 µg/L for 7-days [W.E] | Reduced ovary aromatase A transcript abundance, reduced ovary estradiol and overall egg production | (56) |
| | Killifish (Nothobranchius furzeri; females) | Life-long to 5 µg/L [W.E] | Increased fecundity | (57) |
| | Mosquitofish (males) | Adult exposure to 30 and 380 ng/ L [W.E] for 30 days | Increased sperm production | (58) |
| | Japanese medaka (Oryzias latipes; females) | Adult 28-day exposure to 0.1 and 0.5 µg/L [W.E] | Increased estradiol levels in the plasma | (59) |
| **Citalopram** | Zebradorn (males) | 1. Adult 14-day exposure to 4, 10, or 100 µg/L [W.E] | 1. Reduced transcript levels of gnrh3 in the brain, fshβ in the pituitary, and lowered density of GnRH3 and serotonin fibers in the brain | (60) |
| | | 2. Adult 30-day exposure to 40 or 100 µg/L [W.E] | 2. Reduced transcript abundance of gnrh3 in the brain and fshβ in the pituitary and reduced spermatozoa, spermatogonium, and secondary spermatocytes | |
| **Venlafaxine** | Fathead minnows (Pimephales promelas; both sexes) | Lifelong exposure to 1, 0.88 µg/L or 2. 88 µg/L [W.E] | 1. Increased genital papillae and ovipositor area. 2. Increased egg production | (61) |
| | Zebradorn (females) | Adult 6-week exposure to 10 µg/L [W.E] | Reduction in total fecundity and alterations in kidney tubule morphology | (62) |
| | Zebradorn (females) | Adult 21-day exposure to 1 µg/L [W.E] | Changes in miR-22b, miR-301a miRNA in gonad | (63) |
| **Growth** | **Fluoxetine** | Goldfish (female) | Adult 14-day adult exposure to 5 µg/g body weight [I.P] | Reduced growth rate | (64) |
| | Meagre (Argyrosomus regius) | Exposed to 3 µg/L for 15 days as juveniles | Reduced length, weight, and specific growth rate, and observed DNA damage in the liver | (65) |
| | Zebradorn | Exposed to 100 µg/L for 30 days as adults | Reduced pseudo specific weight gain and feeding | (66) |
| | Killifish (males and females) | Lifelong exposure to 5 µg/L | Reduced body length | (57) |
| **Sertraline** | Fathead minnow larvae | Exposed to 30, 60, 120, 250 µg/L for 48 h from ~48 hpf at pH 6.5, 2. 7.5, and 3. 8.5 | Growth retardation and reduced feeding responses | (67) |
| | Yellow catfish (Pylodictis olivaris) | Exposed to 1, 10 or 100 µg/L for either 7 or 14 d at the juvenile stage | All concentrations reduced weight gain and specific growth rate. Higher concentrations (10 and 100) reduced brain transcript abundances of sst, gh, and igf1, with all concentrations reducing npy | (68) |
| **Venlafaxine** | Fathead minnows | Life-long exposure to 88 µg/L | 31 dpf juveniles exhibit a significant reduction in body weight | (69) |
| | Zebradorn | Exposed to 1 or 10 ng at the zygotic stage [M.I] | Increases developmental rate and length in larvae | (41) |
| | Zebradorn | Exposed to 1 or 10 ng at the zygotic stage [M.I] | Growth retardations at the juvenile stage (80 dpf). Increased hepatic somatic index, and decreased liver transcript abundances of GHrs, IGF2, and lepa, and reduced whole-body insulin. | (70) |

(Continued)
levels, but did not affect the reproductive performance in the female Japanese medaka (Oryzias latipes; 59). Also, exposures to environmentally relevant concentrations of fluoxetine (30 or 380 ng/L) increased total sperm count (58), but did not affect sperm characteristics (79) in the Eastern mosquitoﬁsh (Gambusia holbrooki). These studies suggest that although exposure of adult ﬁsh to environmentally relevant levels may cause endocrine disruption, it did not appear to pose a negative risk to the reproductive outcomes. Life stage of exposure must also be considered, as growing evidence from recent studies reveal that early-life stages may be particularly sensitive to antidepressants exposure and may lead to longer-term reproductive impairment. For instance, life-long exposure to ﬂuoxetine (0.5 or 5 µg/L) in turquoise killiﬁsh (Nothobranchius furzeri) increased fecundity (57). Also, venlafaxine over the entire life cycle at concentrations as low as 0.88 µg/L reduced the length of the ovipositor in female fathead minnows (Pimephales promelas), while at 88 µg/L there was an increase in the total egg output of females (61). These latter studies highlight two critical lessons from contaminant studies: i) species residing in aquatic habitats receiving MWWE exposure may be sensitive to these compounds at environmentally relevant levels, and ii) that early-life exposure windows may be more sensitive to antidepressant impact, leading to long-term effects on reproductive performance. One possible route for early exposure may be through maternal transfer of the compounds to the oocytes, especially given the bioaccumulation potential of the antidepressants in tissues including gonads (6, 59, 78, 80, 81). The mechanism(s) by which antidepressants may lead to changes in the developmental programming of the reproductive axis remains to be examined.

Although the mode of action of antidepressants in affecting reproductive endocrine disruption is unclear, one possible route may be through the modulation of the monoaminergic system. Indeed, the functioning of the hypothalamic-pituitary-gonadal (HPG) axis in ﬁsh (9, 50, 82, 83) is modulated by monoamines, including serotonin, norepinephrine, and dopamine (46, 47, 52). For example, dopamine plays an inhibitory role in ﬁsh reproduction by inhibiting gonadotropin releasing hormone (GnRH) from the hypothalamus and gonadotropins from the pituitary (48). Similarly, serotonin stimulation also regulates HPG axis (12), including stimulation of GnRH at the hypothalamus (84), and stimulation of oocyte maturation locally in the gonads by increased synthesis of estrogen and maturation-inducing steroids (85). The monoamines may also play differing roles at speciﬁc developmental stages or across species. For instance, injections of tyrosine and tryptophan (precursors of dopamine and serotonin, respectively) for 10 days in Gulf killiﬁsh (Fundulus grandis) increases gonadosomatic index in males (86). Conversely, in mummichog (Fundulus heteroclitus), serotonin exposure inhibits oocyte maturation during the follicular development stage via activation of the cAMPK-PKA transduction pathway (87, 88). Taken together, alterations in monoamine levels may be a possible mechanism by which antidepressants impact reproductive endocrine disruption, but these effects may be species-, life stage- and sex-dependent. Studies are clearly
warranted with environmentally relevant species using environmentally relevant concentrations to understand the risks posed on the reproductive performance of fish.

**Growth**

Growth in fish is regulated through a variety of physiological pathways mediating energy acquisition and balance (89, 90). The drive to feed is regulated by the neuropeptides (reviewed by 91), with the somatotropic axis playing a key role in modulating growth and metabolism of skeletal muscle, which comprises >50% of the fish mass (89). Environmental exposures to antidepressants have been shown to restrict growth in fishes, including goldfish (64), zebrafish (66, 70, 71), meager (Argyrosomus regius; 65), yellow catfish (Tachysurus fulvidraco; 68), short-lived killifish (57), and fathead minnows (67, 69, 72; See Table 1 for specific experimental information). This is an important consideration, as restriction on growth is true of exposures to both the SSRI (fluoxetine, sertraline) and the SNRI class (venlafaxine), and has been noted even at environmentally relevant concentrations (68, 71, 72). Exposure during critical developmental windows appears to be more sensitive, as early-life (72) and zygotic (70) exposures led to growth retardations at later life-stages. These growth effects may be related to possible endocrine disruptions. A key aspect of growth is the endocrine control of feeding and metabolism (89, 90). Antidepressants exposure have been shown to reduce feeding responses in fish (92), including goldfish (64), stickleback (Gasterosteus aculeatus; 93), fathead minnows (94, 95), rainbow trout (36), hybrid striped bass (37, 38, 96), mosquito fish (79), and European perch (Perca fluviatilis; 92). As the drive to feed is regulated by the expression of neuropeptides (reviewed by 91), it is possible that these peptides are targets for the impact of the drug. For instance, antidepressants have been shown to influence several key genes involved in feeding activity in fish, including proopiomelanocortin b, corticotropin releasing hormone (CRH), and neuropeptide Y, and these changes correlated with reduced food intake (36, 64, 68), which may be reflected in reduced growth rates. The growth hormone (GH) and the insulin-like growth factors (IGFs), and their receptors and binding proteins are all key components of the somatotropic axis, orchestrating growth and metabolism in fish (97–99). The functioning of the somatotropic axis is regulated by monoaminergic stimulation in fish (10, 100). For instance, serotonin stimulation increases GH secretion (101), while catecholamines, including norepinephrine reduce GH secretion (102). Dopamine also plays a role in modulating GH release in fish (reviewed by 8). For instance, exposure to L-DOPA (precursor of dopamine), dopamine, or D1/D2 receptor agonists (apomorphine) by intraperitoneal injection increased the serum levels of GH in goldfish (102). This increase in GH appears to be driven primarily by the activation of the D1 receptor (103), and involves the cAMP-PKA pathway (104). We have also previously shown that venlafaxine reduced the transcript abundances of growth hormone receptors, IGF2, leptin a, the leptin receptor, and myostatin, in the liver of zebrafish, possibly signaling a disruption in the growth axis functioning, and also leading to metabolic disruption (70). A similar effect was also seen following sertraline exposure in the yellow catfish, experiencing reductions in somatostatin, growth hormone, igf, and neuropeptide y transcript abundance in the brain (68). Together, given the modulatory role of monoamines on the growth axis, it is likely that alterations to their levels due to antidepressant exposure has the potential to impact the feeding and growth performance of fish. Importantly, our study demonstrated that an early-life exposure to venlafaxine can lead to long-term perturbations in the programming of the growth axis (70), but whether this occurs at environmental levels of the antidepressant remain unexplored.

**Corticosteroid Stress Response**

The endocrine stress response is highly conserved in vertebrates and is essential to allow animals to cope with stress (105–109). The primary stress response includes the sympathetic nervous system activation leading to the release of catecholamines, and this is followed by the release of the corticosteroids from the adrenal glands in mammals and the interrenal tissue in teleosts (105, 110–112). In fish, cortisol is the major corticosteroid released in response to stress and its release is mediated by the activation of the hypothalamus-pituitary-interrenal (HPI) axis (106, 107, 111, 113). Once released into the circulation, cortisol action in target tissues is mediated by the activation of either the glucocorticoid receptor (GR) and/or the mineralocorticoid receptor (MR; 114–116). Monoamines play an important role in the regulation of the corticosteroid stress axis (117, 118). In fish, studies have demonstrated that serotonin influences downstream cortisol production (119, 120). For example, intraperitoneal injection of 8-OH-DPAT, a 5HT1A receptor agonist, elevates basal levels of cortisol, and inhibits the attendant rise in cortisol following an acute stressor in juvenile Arctic char (Salvelinus alpinus; 121). This was also mimicked by increased intake of tryptophan, which counteracted the stress-induced elevations in plasma cortisol in rainbow trout (122). Chromaffin cells of the head kidney have been shown to contain serotonin, and this monoamine is capable of stimulating the release of cortisol from interrenal tissues in vitro (123). Catecholamines can also exert influence on the stress axis function, with noradrenaline capable of stimulating CRH secretion in tilapia in vitro (124), and the injection of noradrenaline and adrenaline stimulating the release of cortisol in sea bass (Dicentrarchus labrax; 125). Dopamine, in contrast has been shown to inhibit cortisol release (121), and this may occur even at the level of the pituitary (126). Consequently, the monoaminergic system exerts control over the activity of the HPI axis and may be a target for the antidepressant impact on the stress axis in fish.

Investigations of possible impacts to the stress axis in fish by antidepressants have primarily been carried out using fluoxetine and venlafaxine, with recent evidence suggesting impacts may be sex-specific (See Table 1 for specific experimental information). The responses seen in the activity of the stress axis appears to be life stage-specific in fish. For instance, the circulating cortisol levels increase following an intraperitoneal administration of 50 µg/g of fluoxetine in the adult Gulf toadfish (Opsanus beta) (73). Also, juvenile rainbow trout exposed to environmental levels of venlafaxine (0.1 and 1 µg/L) display amplified cortisol responses
following a social stressor, and this correlated with increases in the transcript abundance of crh and pomc in the brain. Conversely, antidepressants exposure to early-life stages suppressed the stress-induced cortisol production, and also led to long-term impacts on cortisol response, suggesting alterations in the developmental programming of the stress axis (74, 75, 77). For instance, early life exposure to fluoxetine (either 0.54 µg/L or 54 µg/L) reduces basal and stressed levels of cortisol in zebrafish (75). When these fish grew to adults, the attenuated stressor-induced cortisol response was sexually dimorphic with the males more sensitive than females (75, 127). In contrast, zygotic deposition of venlafaxine did not influence cortisol levels at the larval stage, but the stressor-induced cortisol production was attenuated in the female and not male fish as adults (77). Vera-Chang and colleagues (75) suggested that disruptions at the level of the head kidney limited cortisol production in response to fluoxetine, while venlafaxine exposure revealed that the head kidney was still responsive to ACTH (75), suggesting that the disruption in cortisol production was at the level of the hypothalamus and/or pituitary. Although the route of exposure and duration of exposure were different between the two antidepressants (75, 77, 127), the results suggest that the mode of action in affecting the stress axis functioning may be distinct. At least in zebrafish, sex-specific differences in adrenoreceptors are seen in females relative to males, particularly in the hypothalamus and pre-optic areas, with female fish exhibiting higher levels of α2 adrenoreceptors (128). It remains to be seen if the difference in sex-specific effect seen due to early life exposure to either fluoxetine or venlafaxine may be related to their effect on the reuptake of serotonin or serotonin and norepinephrine, respectively. Taken together, these studies demonstrate that the class of antidepressants and duration of exposure may influence the outcome of the endocrine disruption of the stress axis in a sex-specific manner. Regardless, disruptions in cortisol levels may compromise their stress coping capability, as cortisol and the concomitant activation of GR and/or MR are integral players in the energy substrate partitioning to cope with stress (114–116, 129). The mechanisms leading to antidepressants effect on the stress axis warrant further study, especially given that some of these changes are even passed on to successive generations (63, 74, 75, 77, 127). This leads to the proposal that epigenetic changes due to early life exposure to the antidepressants may be involved in the long-term programming of the stress axis in teleosts.

**CONCLUSIONS AND FUTURE DIRECTIONS**

Antidepressants alter central monoamine levels, and this may play a role in the behavioural perturbations in fish (6, 39, 128). The emerging evidence also points to antidepressants as endocrine disrupting compounds in fish (Table 1). Specifically, studies reveal that the antidepressants impact the endocrine control of growth, stress, and reproductive axes in fish (Figure 1). As the monoaminergic system modulates endocrine function, a possible mode of action of the antidepressants in affecting endocrine disruption may be through alterations in the central and peripheral monoamine content, but this remains to be established. It is particularly important to note that early life exposures to antidepressants impacts the developmental programming of the endocrine system, and this may be reflected in long term and multigenerational changes in hormone levels and function (75, 77). We recently showed that venlafaxine-mediated disruption in embryonic serotonin content alters neurogenesis (39), and whether

**FIGURE 1** | Overview of the tissue-specific impacts of antidepressants on the endocrine axes in fish. Depiction of the expected mode of action of antidepressants, along with the specific tissues and the observed phenotypes associated with exposures to antidepressants.
this alteration in brain development may play a role in the developmental programming of the endocrine axes warrants further study. For instance, the availability of knockout models in fish, including tryptophan hydroxylase paralogs (92, 129), a rate limiting enzyme in serotonin synthesis, will be an important step in delineating the effects of antidepressants mediated by the serotonergic pathway. While targeting the changes in the monoamine content may be one possible mechanism leading to endocrine disruption, the possibility that antidepressants may have direct effect on hormone action by targeting receptor function cannot be excluded (62). The sex of the animal is also another key factor that may dictate the outcome of the antidepressants impact (73, 75, 77, 127), and should be taken into account in future studies on endocrine disruption. Elucidating the mechanism of action of antidepressants in disrupting endocrine function in non-target organisms would be an important future direction to assess their impact on fitness consequences to the animal. A major limitation of the current body of work is the scarcity of studies on the endocrine effects related to environmentally relevant concentrations of the antidepressants in species commonly found in the aquatic habitats receiving MWWE. Environmental disruptors, including antidepressants are persistent in the aquatic habitats, suggestive of life-long exposures to these compounds (28). However, the implications of such life long exposures on animal fitness, and multigenerational consequences awaited further study.

Such studies would be essential in developing markers for environmental risk assessment and for establishing adverse outcome pathways related to endocrine disruptive impacts of antidepressants. From a mechanistic standpoint, future studies should aim to identify the critical window during early development that is most sensitive to antidepressants and understand the mechanisms of action by which these pharmaceuticals alter the developmental programming of the endocrine system. This would allow for the development of novel biomarkers that are indicative of the developmental origin of endocrine dysfunction due to antidepressants exposure in fish.

**AUTHOR CONTRIBUTIONS**

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

**FUNDING**

The authors thank the funding support from the Natural Sciences and Engineering Research Council of Canada Discovery Grant awarded to MMV (RGPIN-2019-06291).

**REFERENCES**

1. Daughton CG, Ternes TA. Pharmaceuticals and Personal Care Products in the Environment: Agents of Subtle Change? *Environ Health Perspect* (1999) 107:907–38. doi: 10.1289/ehp.991076907

2. Söflker M, Tyler CR. Endocrine Disrupting Chemicals and Sexual Behaviors in Fish a Critical Review on Effects and Possible Consequences. *Crit Rev Toxicol* (2012) 42:653–68. doi: 10.3109/10408444.2012.692114

3. Menningen JA, Stroud P, Zamora JM, Moon TW, Trudeau VL. Pharmaceuticals as Neuroendocrine Disruptors: Lessons Learned From Fish on Prozac. *J Toxicol Environ Heal - Part B Crit Rev* (2011) 14:387–412. doi: 10.1080/10937404.2011.578559

4. Melvin SD. Effect of Antidepressants on Circadian Rhythms in Fish: Insights and Implications Regarding the Design of Behavioural Toxicity Tests. *Aquat Toxicol* (2017) 182:20–30. doi: 10.1016/j.aquatox.2016.11.007

5. Sehonova P, Svodbova Z, Dolezelova P, Vosmerova P, Faggio C. Effects of Waterborne Antidepressants on non-Target Animals Living in the Aquatic Environment: A Review. *Sci Total Environ* (2018) 631–632:789–94. doi: 10.1016/j.scitotenv.2018.03.076

6. Gould SL, Winter MJ, Norton WHJ, Tyler CR. The Potential for Adverse Effects in Fish Exposed to Antidepressants in the Aquatic Environment. *Environ Sci Technol* (2021) 55:16299–312. doi: 10.1021/acs.est.1c04724

7. Hillhouse TM, Porter JH. A Brief History of the Development of Antidepressant Drugs: From Monoamines to Glutamate. *Exp Clin Psychopharmacol* (2015) 23:1–21. doi: 10.1037/a0038550.A

8. Peng C, Peter RE. Neuroendocrine Regulation of Growth Hormone Secretion and Growth in Fish. *Zool Stud* (1997) 36:79–89.

9. Trudeau VL. Neuroendocrine Regulation of Gonadotrophin II Release and Gonadal Growth in the Goldfish, *Carassius Auratus*. *Rev Reprod* (1997) 2:55–68. Doi: 10.1350/rrrevprod/2/1.55

10. Canosa LF, Chang JP, Peter RE. Neuroendocrine Control of Growth Hormone in Fish. *Gen Comp Endocrinol* (2007) 151:1–26. doi: 10.1016/j.ygce.2006.12.010

11. Krece N, Dietrich DR. Physiological Endpoints for Potential SSRI Interactions in Fish. *Crit Rev Toxicol* (2008) 38:215–47. doi: 10.1080/10408440801891057

12. Prasad P, Ogawa S, Parhar IS. Role of Serotonin in Fish Reproduction. *Front Neurosci* (2015) 9:195. doi: 10.3389/fnins.2015.00195

13. McDonald MD. An AOP Analysis of Selective Serotonin Reuptake Inhibitors (SSRIs) for Fish. *Comp Biochem Physiol Part - C Toxicol Pharmacol* (2017) 197:19–31. doi: 10.1016/j.cbpc.2017.03.007

14. Huang H, Coleman S, Bridge IA, Yonkers K, Katon W. A Meta-Analysis of the Relationship Between Antidepressant Use in Pregnancy and the Risk of Preterm Birth and Low Birth Weight. *Gen Hosp Psychiatry* (2014) 36:13–8. doi: 10.1016/j.genhosppsych.2013.08.002

15. Mars B, Heron J, Kessler D, Davies NM, Martin RM, Thomas KH, et al. Influences on Antidepressant Prescribing Trends in the UK: 1995–2011. *Soc Psychiatry Psychiatr Epidemiol* (2017) 52:193–200. doi: 10.1007/s00127-016-1306-4

16. Pratt LA, Brody DJ, Gu Q. Antidepressant Use Among Persons Aged 12 and Older:United States,2011–2014. *NCHS Data Brief* (2017) 283:1–8.

17. Pereira VS, Hiroaki-Sato VA. A Brief History of Antidepressant Drug Development: From Tricyclics to Beyond Ketamine. *Acta Neuropsychiatr* (2018) 30:307–22. doi: 10.1017/aju.2017.39

18. Telles-Correia D, Barbosa A, Cortez-Pinto H, Campos C, Rocha NBF, Machado S. Psychotropic Drugs and Liver Disease: A Critical Review of Pharmacokinetics and Liver Toxicity. *World J Gastrointest Pharmacol Ther* (2017) 8:26. doi: 10.4292/wjgpt.v8.i1.26

19. Owens MJ, Morgan WN, Plott SJ, Nemeroff CB. Neurotransmitter Receptor and Transporter Binding Profile of Antidepressants and Their Metabolites. *J Pharmacol Exp Ther* (1997) 283:1305–22.

20. Kolpin DW, Furlong ET, Meyer MT, Thurman EM, Zaugg SD, Barber LB, et al. Pharmaceuticals, Hormones, and Other Organic Wastewater Contaminants in U.S. Streams, 1999-2000: A National Reconnaissance. *Environ Sci Technol* (2002) 36:1202–11. doi: 10.1021/es01055j

21. Archer E, Petrie B, Kasprzyk-Hordern B, Wolfardt GM. The Fate of Pharmaceuticals and Personal Care Products (PPCPs), Endocrine Disrupting Contaminants (EDCs), Metabolites and Illicit Drugs in a WWTP and Environmental Waters. *Chemosphere* (2017) 174:347–46. doi: 10.1016/j.chemosphere.2017.01.101
Antidepressants Impact on Fish

22. Gasser G, Pankratov I, Elhanany S, Werner P, Gun J, Gelman F, et al. Field and Laboratory Studies of the Fate and Enantiomeric Enrichment of Venlafaxine and O-Demethylvenlafaxine Under Aerobic and Anaerobic Conditions. *Chemosphere* (2012) 88:98–105. doi: 10.1016/j.chemosphere.2012.02.074

23. Schlüsener MP, Hardenbicker P, Nilson E, Schulz M, Viergutz C, Ternes TA. Occurrence of Venlafaxine, Other Antidepressants and Selected Metabolites in the Rhine Catchment in the Face of Climate Change. *Environ Pollut* (2015) 196:247–56. doi: 10.1016/j.envpol.2014.09.019

24. Fernández-Rubio J, Rodriguez-Gil JL, Postigl C, Mastroianni N, López de Alda M, Barceló D, et al. Psychoactive Pharmaceuticals and Illicit Drugs in Coastal Waters of North-Western Spain: Environmental Exposure and Risk Assessment. *Chemosphere* (2019) 224:379–89. doi: 10.1016/j.chemosphere.2019.02.041

25. Papaegorgiu M, Kosma C, Lambropoulou D. Seasonal Occurrence, Removal, Mass Loading and Environmental Risk Assessment of 52 Pharmaceuticals and Personal Care Products in a Municipal Wastewater Treatment Plant in Central Greece. *Sci Total Environ* (2016) 543:547–69. doi: 10.1016/j.scitotenv.2015.11.047

26. Metcalfe CD, Chu S, Judd C, Li H, Oakes KD, Servos MR, et al. Antidepressants and Their Metabolites in Municipal Wastewater, and Downstream Exposure in an Urban Watershed. *Environ Toxicol Chem* (2010) 29:79–89. doi: 10.1002/etc.27

27. Rúa-Gómez PC, Püttmann W. Impact of Wastewater Treatment Plant Discharge of Lidocaine, Tramadol, Venlafaxine and Their Metabolites on the Quality of Surface Waters and Groundwater. *J Environ Monit* (2012) 14:1391. doi: 10.1039/c2em10950f

28. Brooks BW. Fish on Prozac (and Zoloft): Ten Years Later. *Archives* (2014) 151:611–7. doi: 10.1016/j.aquatox.2014.01.007

29. Rabeea SA, Merchant HA, Khan MU, Hasan SS, et al. Surging Trends in Inhibitor (SSRI) Sertraline Decrease Serotonin Reuptake Transporter Binding and Shelter-Seeking Behavior in Adult Male Fathead Minnows. *Environ Sci Technol* (2012) 21:4247–5. doi: 10.1021/es20416b827/8

30. Thompson WA, Arnold VH, Vijayan MM. Venlafaxine in Embryos Stimulates Neurogenesis and Disrupts Larval Behavior in Zebrafish. *Environ Sci Technol* (2017) 51:12889–97. doi: 10.1021/acs.est.7b04099

31. Pivonello R, Ferone D, Lombardi G, Colao A, Lamberts SJ, Hofland LJ. Novel Insights in Dopamine Receptor Physiology. *Eur J Endocrinol Suppl* (2007) 156:S13–21. doi: 10.1530/ejie.1.02353

32. Yabut JM, Crane JD, Green AE, Keating DJ, Khan WL, Steinberg GR. Emerging Roles for Serotonin in Regulating Metabolism: New Implications for an Ancient Molecule. *Endocr Rev* (2019) 40:1092–107. doi: 10.1210/er.2018-00283

33. Miller GD. Appetite Regulation: Hormones, Peptides, and Neurotransmitters and Their Role in Obesity. *Am J Lifestyle Med* (2019) 13:586–601. doi: 10.1177/1559827617163766

34. Soares MC, Gerlai R, Maximino C. The Integration of Sociality, Monoamines and Stress Neuroendocrinology in Fish Models: Applications in the Neurosciences. *J Fish Biol* (2018) 93:170–91. doi: 10.1111/jfb.13757

35. Muñoz-Cueto JA, Zmora N, Paulilla-Salmeron J, Marivel M, Mananos E, Zohar Y. The Gonadotropin-Releasing Hormones: Lessons From Fish. *Gen Comp Endocrinol* (2020) 151:13422. doi: 10.1016/j.ygcen.2020.113422

36. Zohar Y. Fish Reproductive Biology- Reflecting on Five Decades of Fundamental and Translational Research. *Gen Comp Endocrinol* (2020) 265:115068. doi: 10.1016/j.envpol.2020.115068

37. Dufour S, Sebert ME, Weltzien FA, Rousseau K, Pasqualini C. Neuroendocrine Control by Dopamine of Teleost Reproduction. *J Fish Biol* (2010) 76:129–60. doi: 10.1111/j.1091-6466.2009.02499.x

38. Müller EE, Locatelli V, Cocchi D. Neuroendocrine Control of Growth Hormone Secretion. *Physiol Rev* (1999) 79:511–607. doi: 10.1152/physrev.1999.79.2.511

39. Faught E, Vijayan MM. Maternal Stress and Fish Reproduction: The Role of Cortisol Revisited. *Fish* (2018) 19:1016–30. doi: 10.1111/tfl.12309

40. Lubzens E, Bobe J, Young G, Sullivan CV. Maternal Investment in Fish Oocytes and Eggs: The Molecular Cargo and Its Contributions to Fertility and Early Development. *Aquaculture* (2017) 472:107–43. doi: 10.1016/j.aquaculture.2016.10.029

41. Yaron Z, Levavi-Sivan B. Hormonal Control of Reproduction and Growth | Endocrine Regulation of Fish Reproduction. San Diego: Elsevier Inc. (2011). doi: 10.1109/B978-0-12-374553-8.00058-7

42. Henry TB, Black MC. Acute and Chronic Toxicity of Fluoxetine (Selective Serotonin Reuptake Inhibitor) in Western Mosquito Fish. *Environ Sci Technol* (2008) 54:325. doi: 10.1021/es800794u

43. Mennigen JA, Martyniuk CJ, Crump K, Xiong H, Zhao E, Popesku J, et al. The Antidepressant Fluoxetine Alters Mechanisms of Pre- and Post-Copulatory Sexual Selection in the Eastern Mosquito Fish. *Environ Sci Technol* (2018) 52:73–82. doi: 10.1021/acs.est.7b05698

44. Doherty PC, Rodriguez ME, Tresse LM, Watanabe N, Sato A, Arai Y, et al. The Gonadotropin-Releasing Hormones: Lessons From Fish. *Gen Comp Endocrinol* (2008) 54:325. doi: 10.1016/j.ygcen.2020.113422

45. Mennigen JA, Lado WE, Zamora JM, Duarte-guterman P, Langlois VS, Metcalfe CD, et al. Waterborne Fluoxetine Disrupts the Reproductive Axis in Sexually Mature Male Goldfish, Carassius Auratus. *Aquat Toxicol* (2010) 106:354–6. doi: 10.1016/j.aquatox.2010.08.016

46. Lister A, Regan C, Van Zwol J, van der Kraak G. Inhibition of Egg Production in Zebrafish by Fluoxetine and Municipal Effluents: A Mechanistic Evaluation. *Aquat Toxicol* (2009) 95:320–9. doi: 10.1016/j.aquétox.2009.04.011

47. Thoré ESJ, Philippe C, Brendonck L, Pincetl T. Antidepressant Exposure Reduces Body Size, Increases Fecundity and Alters Social Behavior in the Short-Lived Killifish Nothobranchius Furzeri. *Environ Pollut* (2020) 265:115068. doi: 10.1016/j.envpol.2020.115068

48. Bertram MG, Ecker TE, Wong BBM, O’Byran MK, Baumgartner JB, Martin JM, et al. The Antidepressant Fluoxetine Alters Mechanisms of Pre- and Post-Copulatory Sexual Selection in the Eastern Mosquitofish (Gambusia Holbrooki). *Environ Pollut* (2018) 238:238–47. doi: 10.1016/j.envpol.2018.03.006

49. Geisen CM, Weston J, Slattery M, Brooks BW, Huggett DB. Reproductive Assessment of Japanese Medaka (Oryzias Latipes) Following a Four-Week Fluoxetine (SSRI) Exposure. *Arch Environ Contam Toxicol* (2004) 46:511–7. doi: 10.1007/s00244-003-3042-5
60. Prasad P, Ogawa S, Parhar IS. Serotonin Reuptake Inhibitor Citalopram Inhibits GnRH Synthesis and Spermato genesis in the Male Zebrasfish. Biol de Peixos (2015) 6:161-62. doi: 10.1095/biadvp.115.129965

61. Parrott JL, Metcalfe CD. Assessing the Effects of the Antidepressant Venlafaxine to Fathead Minnows Exposed to Environmentally Relevant Concentrations Over a Full Life Cycle. Environ Pollut (2017) 229:403-11. doi: 10.1016/j.envpol.2016.06.009

62. Galus M, Kirischian N, Higgins S, Purdy J, Chow J, Rangajaran S, et al. Chronic, Low Concentration Exposure to Pharmaceuticals Impacts Multiple Organ Systems in Zebrasfish. Aquat Toxicol (2013) 132-133:200-11. doi: 10.1016/j.aquatox.2012.12.021

63. McCallum ES, Krutzellmann E, Brodin T, Fick J, Sundelin A, Balshine S. Exposure to Wastewater Effluent Affects Fish Behaviour and Tissue-Specific Uptake of Pharmaceuticals. Sci Total Environ (2017) 605–606:578–88. doi: 10.1016/j.scitotenv.2017.06.073

64. Mennigen JA, Harris EA, Chang JP, Moon TW, Trudeau VL. Fluoxetine Chronic Exposure Affects Growth, Behavior and Tissue Structure of Zebrasfish. Comp Biochem Physiol Part - C Toxicol Pharmacol (2020) 237:108836. doi: 10.1016/j.cbpc.2020.108836

65. Duarte IA, Reis-Santos P, Novais SC, Rato LD, Lemos MFL, Freitas A, et al. Fluoxetine Chronic Exposure Affects Growth, Behavior and Tissue Structure of Zebrasfish. Comp Biochem Physiol Physiol - Part D (2020) 33:100634. doi: 10.1016/j.jbcp.2019.100634

66. Valenti TW, Perez-Hurtado P, Chambliss CK, Brooks BW. Aquatic Toxicity of Sertraline Disrupts Behavior and the Brain and Liver Transcriptome of Juvenile Yellow Catfish. Neurotoxicol Teratol (2019) 382:114742. doi: 10.1016/j.taap.2019.114742

67. Tang Y, Mi P, Li M, Zhang S, Li J, Feng X. Environmental Level of the Selective Serotonin Reuptake Inhibitor Citalopram Exposure to Wastewater Efﬂuent Affects Fish Behaviour and Performance in Fathead Minnows. Regul Pept (2009) 155:99-104. doi: 10.1016/j.regpep.2009.01.001

68. Chen H, Liang X, Gu X, Xue Q, Mao Z, Martyniuk CJ. Environmentally Relevant Concentrations of Sertraline Disrupts Behavior and the Brain and Liver Transcriptome of Juvenile Yellow Catﬁsh (Tachysurus fulvidraco): Implications for the Feeding and Growth Axis. J Hazard Mater (2021) 409:124974. doi: 10.1016/j.jhazmat.2020.124974

69. Parrott JL, Metcalfe CD. Nest-Defense Behaviors in Fathead Minnows After Exposure to Venlafaxine Deposition in the Zygote. Frontiers in Endocrinology | www.frontiersin.org June 2022 | Volume 13 | Article 895064

70. Mennigen JA, Harris EA, Chang JP, Moon TW, Trudeau VL. Fluoxetine Affects Weight Gain and Expression of Feeding Peptides in the Female Goldﬁsh Brain. Regul Pept (2009) 155:99-104. doi: 10.1016/j.regpep.2009.01.001

71. Thompson WA, Vijayan MM. Zygotic Exposure to Venlafaxine Disrupts Behavior and the Brain and Liver Transcriptome of Juvenile Yellow Catﬁsh (Tachysurus fulvidraco): Implications for the Feeding and Growth Axis. J Hazard Mater (2021) 409:124974. doi: 10.1016/j.jhazmat.2020.124974

72. Thompson WA, Vijayan MM. Zygotic Exposure to Venlafaxine Disrupts Cortisol Stress Axis Activity in Multiple Generations of Zebrasﬁsh. Environ Pollut (2021) 274:116535. doi: 10.1016/j.envpol.2021.116535

73. Galus M, Kirischian N, Higgins S, Purdy J, Chow J, Rangajaran S, et al. Chronic, Low Concentration Exposure to Pharmaceuticals Impacts Multiple Organ Systems in Zebrasﬁsh. Aquat Toxicol (2013) 132-133:200-11. doi: 10.1016/j.aquatox.2012.12.021

74. Martin JM, Bertram MG, Saaristo M, Ecker TE, Hannington SL, Tanner JL, et al. Impact of the Widespread Pharmaceutical Pollutant Fluoxetine on Behaviour and Sperm Traits in a Freshwater Fish. Sci Total Environ (2019) 650:1771-8. doi: 10.1016/j.scitotenv.2018.09.294

75. McCallum ES, Krutzellmann E, Brodin T, Fick J, Sundelin A, Balshine S. Exposure to Wastewater Effluent Affects Fish Behaviour and Tissue-Specific Uptake of Pharmaceuticals. Sci Total Environ (2017) 605–606:578–88. doi: 10.1016/j.scitotenv.2017.06.073

76. Arnnok P, Singh RR, Burakham R, Perez-Fuentetaja A, Aga DS. Selective Uptake and Bioaccumulation of Antidepressants in Fish From Environmental Impacted Niagara River. Environ Sci Technol (2017) 51:10652–62. doi: 10.1021/acs.est.7b02912

77. Zohar Y, Muñoz-Cueto JA, Elizur A, Kah O. Neuroendocrinology of Reproduction in Teleost Fish. Gen Comp Endocrinol (2010) 165:438–55. doi: 10.1016/j.ygcen.2009.04.017

78. Trudeau VL, Spanswick D, Fraser Ej, Lariiviere K, Crump D, Chiu S, et al. The Role of Amino Acid Neurotransmitters in the Regulation of Pituitary Gonadotropin Release in Fish. Biochem Cell Biol (2000) 78:241–59. doi: 10.1139/o19-097

79. Vera-Chang MN, St-jacques AD, Lu C, Moon TW, Trudeau VL, Carr JA. Transgenerational Hypocortisolism and Behavioral Disruption are Induced by the Antidepressant Fluoxetine in Male Zebraﬁsh Danio Rerio. Proc Natl Acad Sci (2019) 116:16079-84. doi: 10.1073/pnas.1902480116

80. Vera-Chang MN, St-jacques AD, Gagne R, Martyniuk CJ, Yau CL. Transgenerational Hypocortisolism and Behavioral Disruption are Induced by the Antidepressant Fluoxetine in Male Zebrasﬁsh Danio Rerio. Proc Natl Acad Sci (2018) 115:1-8. doi: 10.1073/pnas.1811695115

81. Vera-Chang MN, St-jacques AD, Lu C, Moon TW, Trudeau VL, Carr JA. Fluoxetine Exposure During Sexual Development Disrupts the Stress Axis and Results in Sex- and Time- Dependent Effects on the Explorer Axis Behavior in Adult Zebrasﬁsh Danio Rerio. Front Neurosci (2019) 13:1015. doi: 10.3389/fnins.2019.01015

82. Thompson WA, Vijayan MM. Zygotic Exposure to Venlafaxine Disrupts Cortisol Stress Axis Activity in Multiple Generations of Zebrasﬁsh. Environ Pollut (2021) 274:116535. doi: 10.1016/j.envpol.2021.116535
